The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

EDATREXATE     2-[[4-[1-(2,4- diaminopteridin-6-yl)butan- 2...

Synonyms: Edatrexato, Edatrexatum, CHEMBL9798, AGN-PC-00PPKW, SureCN1650127, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of EDATREXATE


High impact information on EDATREXATE


Chemical compound and disease context of EDATREXATE


Biological context of EDATREXATE


Anatomical context of EDATREXATE


Associations of EDATREXATE with other chemical compounds


Gene context of EDATREXATE

  • Phase II trial of edatrexate in patients with advanced hepatocellular carcinoma [27].
  • Although CEM/MTX cells were highly resistant (162- to 300-fold) to assorted antifolate substrates for the classical transporter, including methotrexate, aminopterin, 10-ethyl-10-deazaaminopterin, ICI D1694, and 1843U89, they were only 3.6-fold resistant to (6R)-5,10-dideaza-5,6,7,8-tetrahydrofolate (DDATHF) [28].
  • Due to the potential broad spectrum of activity of edatrexate plus CDDP, further studies are warranted to determine the mechanism responsible for the synergism and to investigate this combination in a variety of tumor models [16].
  • In contrast, PDX was even more active (75-85% complete regressions and 25-30% cures) than EDX against the MX-1 and LX-1 tumors and highly active (30% complete regressions and 20% cures) against the A549 tumor [29].
  • With no objective evidence for antitumor activity as assessed by post-therapy PSA changes in any of the patients treated, edatrexate seems a poor candidate for future study [30].

Analytical, diagnostic and therapeutic context of EDATREXATE


  1. Toxicity, elimination, and metabolism of 10-ethyl-10-deazaaminopterin in rats and dogs. Fanucchi, M.P., Kinahan, J.J., Samuels, L.L., Hancock, C., Chou, T.C., Niedzwiecki, D., Farag, F., Vidal, P.M., DeGraw, J.I., Sternberg, S.S. Cancer Res. (1987) [Pubmed]
  2. Phase II study of weekly edatrexate as first-line chemotherapy for metastatic breast cancer: a National Cancer Institute of Canada Clinical Trials Group study. Vandenberg, T.A., Pritchard, K.I., Eisenhauer, E.A., Trudeau, M.E., Norris, B.D., Lopez, P., Verma, S.S., Buckman, R.A., Muldal, A. J. Clin. Oncol. (1993) [Pubmed]
  3. Randomized phase III trial of edatrexate versus methotrexate in patients with metastatic and/or recurrent squamous cell carcinoma of the head and neck: a European Organization for Research and Treatment of Cancer Head and Neck Cancer Cooperative Group study. Schornagel, J.H., Verweij, J., de Mulder, P.H., Cognetti, F., Vermorken, J.B., Cappelaere, P., Armand, J.P., Wildiers, J., de Graeff, A., Clavel, M. J. Clin. Oncol. (1995) [Pubmed]
  4. Phase I and pharmacological study of two schedules of the antifolate edatrexate in combination with cisplatin. Laurie, S.A., Pfister, D.G., Kris, M.G., Tong, W.P., Chronowski, G., Pisters, K.M., Heelan, R.T., Sirotnak, F.M. Clin. Cancer Res. (2001) [Pubmed]
  5. Folylpolyglutamyl synthetase gene transfer and glioma antifolate sensitivity in culture and in vivo. Aghi, M., Kramm, C.M., Breakefield, X.O. J. Natl. Cancer Inst. (1999) [Pubmed]
  6. Schedule-dependent edatrexate toxicity. Perez, E.A. J. Clin. Oncol. (1996) [Pubmed]
  7. Membrane transport of natural folates and antifolate compounds in murine L1210 leukemia cells: role of carrier- and receptor-mediated transport systems. Westerhof, G.R., Jansen, G., van Emmerik, N., Kathmann, I., Rijksen, G., Jackman, A.L., Schornagel, J.H. Cancer Res. (1991) [Pubmed]
  8. Identification of a membrane-associated folate-binding protein in human leukemic CCRF-CEM cells with transport-related methotrexate resistance. Jansen, G., Westerhof, G.R., Kathmann, I., Rademaker, B.C., Rijksen, G., Schornagel, J.H. Cancer Res. (1989) [Pubmed]
  9. Posttranscriptionally mediated decreases in folylpolyglutamate synthetase gene expression in some folate analogue-resistant variants of the L1210 cell. Evidence for an altered cognate mRNA in the variants affecting the rate of de novo synthesis of the enzyme. Roy, K., Egan, M.G., Sirlin, S., Sirotnak, F.M. J. Biol. Chem. (1997) [Pubmed]
  10. Experimental therapeutics with a new 10-deazaaminopterin in human mesothelioma: further improving efficacy through structural design, pharmacologic modulation at the level of MRP ATPases, and combined therapy with platinums. Khokhar, N.Z., She, Y., Rusch, V.W., Sirotnak, F.M. Clin. Cancer Res. (2001) [Pubmed]
  11. Phase I trial of edatrexate plus carboplatin in advanced solid tumors: amelioration of dose-limiting mucositis by ice chip cryotherapy. Edelman, M.J., Gandara, D.R., Perez, E.A., Lau, D., Lauder, I., Turrell, C., Uhrich, M., Meyers, F. Investigational new drugs. (1998) [Pubmed]
  12. Phase II study of carboplatin and edatrexate (10-EdAM) with leucovorin rescue for patients with recurrent squamous cell carcinoma of the head and neck. Huber, M.H., Dimery, I.W., Benner, S.E., Lippman, S.M., Shirinian, M., Esparaz, B., Frenning, D., Guillory-Perez, C., Hong, W.K. Investigational new drugs. (1994) [Pubmed]
  13. Antifolate analogs: mechanism of action, analytical methodology, and clinical efficacy. Fleisher, M. Therapeutic drug monitoring. (1993) [Pubmed]
  14. Edatrexate improves the antitumor effects of cyclophosphamide and cisplatin against non-small cell lung cancer. Lee, J.S., Libshitz, H.I., Fossella, F.V., Murphy, W.K., Pang, A.C., Lippman, S.M., Shin, D.M., Dimery, I.W., Glisson, B.S., Hong, W.K. Cancer (1991) [Pubmed]
  15. Analogues of 10-deazaaminopterin and 5-alkyl-5,10-dideazaaminopterin with the 4-substituted 1-naphthoyl group in the place of 4-substituted benzoyl. Piper, J.R., Ramamurthy, B., Johnson, C.A., Otter, G.M., Sirotnak, F.M. J. Med. Chem. (1996) [Pubmed]
  16. Schedule-dependent synergism of edatrexate and cisplatin in combination in the A549 lung-cancer cell line as assessed by median-effect analysis. Perez, E.A., Hack, F.M., Webber, L.M., Chou, T.C. Cancer Chemother. Pharmacol. (1993) [Pubmed]
  17. Pharmacokinetics of 10-ethyl-10-deaza-aminopterin, edatrexate, given weekly for non-small-cell lung cancer. Hartley, J.M., Nicholson, P.W., Allen, R., Lamond, P., Harland, S.J., Souhami, R.L. Cancer Chemother. Pharmacol. (1993) [Pubmed]
  18. Effect of vehicles and penetration enhancers on the in vitro and in vivo percutaneous absorption of methotrexate and edatrexate through hairless mouse skin. Chatterjee, D.J., Li, W.Y., Koda, R.T. Pharm. Res. (1997) [Pubmed]
  19. Phase II trial of edatrexate in relapsed or refractory germ cell tumors: a Southwest Oncology Group study (SWOG 9124). Meyers, F.J., Lew, D., Lara, P.N., Williamson, S., Marshall, E., Balcerzak, S.P., Rivkin, S.E., Samlowski, W., Crawford, E.D. Investigational new drugs. (1998) [Pubmed]
  20. Phase II trial of edatrexate in patients with advanced pancreatic adenocarcinoma. Casper, E.S., Schwartz, G.K., Johnson, B., Kelsen, D.P. Investigational new drugs. (1992) [Pubmed]
  21. Leucovorin rescue of human cancer and bone marrow cells following edatrexate or methotrexate. Jolivet, J., Jansen, G., Peters, G.J., Pinard, M.F., Schornagel, J.H. Biochem. Pharmacol. (1994) [Pubmed]
  22. Quantitation of the synergistic interaction of edatrexate and cisplatin in vitro. Chou, T.C., Tan, Q.H., Sirotnak, F.M. Cancer Chemother. Pharmacol. (1993) [Pubmed]
  23. Ex vivo activity of methotrexate versus novel antifolate inhibitors of dihydrofolate reductase and thymidylate synthase against childhood leukemia cells. Mauritz, R., Bekkenk, M.W., Rots, M.G., Pieters, R., Mini, E., van Zantwijk, C.H., Veerman, A.J., Peters, G.J., Jansen, G. Clin. Cancer Res. (1998) [Pubmed]
  24. New drugs in the treatment of non-small cell lung cancer. Steward, W.P., Dunlop, D.J. Ann. Oncol. (1995) [Pubmed]
  25. Modulation of intrinsic in vitro resistance to carboplatin by edatrexate in the A549 human nonsmall cell lung cancer cell line. Perez, E.A., Hack, F.M., Fletcher, T.S., Chou, T.C. Oncol. Res. (1994) [Pubmed]
  26. Phase II trial of paclitaxel in patients with soft-tissue sarcoma. Casper, E.S., Waltzman, R.J., Schwartz, G.K., Sugarman, A., Pfister, D., Ilson, D., Woodruff, J., Leung, D., Bertino, J.R. Cancer Invest. (1998) [Pubmed]
  27. Phase II trial of edatrexate in patients with advanced hepatocellular carcinoma. Pazdur, R., Moore, D.F., Bready, B., Giannone, L., Maldonado, A., Lin, Y.G., Fueger, R.H., Winn, R.J., Levin, B. Ann. Oncol. (1994) [Pubmed]
  28. Determinants of the disparate antitumor activities of (6R)-5,10-dideaza-5,6,7,8-tetrahydrofolate and methotrexate toward human lymphoblastic leukemia cells, characterized by severely impaired antifolate membrane transport. Matherly, L.H., Angeles, S.M., McGuire, J.J. Biochem. Pharmacol. (1993) [Pubmed]
  29. A new analogue of 10-deazaaminopterin with markedly enhanced curative effects against human tumor xenografts in mice. Sirotnak, F.M., DeGraw, J.I., Colwell, W.T., Piper, J.R. Cancer Chemother. Pharmacol. (1998) [Pubmed]
  30. Post-therapy change in prostate-specific antigen levels as a clinical trial endpoint in hormone-refractory prostatic cancer: a trial with 10-ethyl-deaza-aminopterin. Schultz, P.K., Kelly, W.K., Begg, C., Liebertz, C., Cohen, L., Scher, H.I. Urology (1994) [Pubmed]
  31. High-dose edatrexate with oral leucovorin rescue: a phase I and clinical pharmacological study in adults with advanced cancer. Pisters, K.M., Tyson, L.B., Tong, W., Fleisher, M., Miller, V.A., Grant, S.C., Pfister, D.G., Rigas, J.R., Densmore, C.L., Krol, G., Heelan, R.T., Sirotnak, F.M., Bertino, J.R., Kris, M.G. Clin. Cancer Res. (1996) [Pubmed]
  32. Phase II trial of edatrexate in patients with metastatic colorectal cancer. Clamon, G.H., Riggs, C.E., Dreicer, R., Hohl, R.J. Investigational new drugs. (1996) [Pubmed]
WikiGenes - Universities